

**WHO Prequalification Programme**  
**WHO PUBLIC ASSESSMENT REPORT (WHOPAR)**

**[TB179 trade name]\***

Isoniazid 300 mg tablets

[TB179 trade name], manufactured at Macleods Pharmaceuticals Limited, Daman, India, was included in the WHO list of prequalified medicinal products for the treatment of tuberculosis on 23 April 2008.

[TB179 trade name] is indicated in combination with other tuberculosis medicines for the treatment of tuberculosis due to *Mycobacterium tuberculosis*, including in regimens for drug-resistant tuberculosis. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredient of [TB179 trade name] is isoniazid.

The efficacy and safety of isoniazid are well established based on extensive clinical experience in the treatment of tuberculosis. For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of isoniazid for treatment and prevention of tuberculosis, the team of assessors advised that [TB179 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [TB179 trade name] in the list of prequalified medicinal products.

**Summary of prequalification status for [TB179 trade name]:**

Initial acceptance	Date	Outcome
Status on PQ list	23 April 08	listed
Quality	14 March 08	MR
Bioequivalence	23 January 07	MR
Safety, efficacy	NA	NA
<b>GMP (re-)inspection</b>		
API	14 October 06	Waived
FPP	20 June 07	MR
<b>GCP/GLP (re-)inspection</b>	28 April 07	MR
API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard]	GMP: good manufacturing practice [quality standard] MR: meets requirements MR*: desk review (based on recent inspection reports) NA: not applicable, not available PQ: prequalification	

The table represents the status of relevant completed activities only.

<b>Requalification</b>	30 July 2019
------------------------	--------------

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.